Home>RESOURCE > Publication

RESOURCE

Publication
The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. ​

Abstract

K-111, formerly BM 17.0744, (2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid) is a new insulin-sensitizer with peroxisome proliferator-activated receptor (PPAR) alpha activity but without PPAR gamma activity. We determined the efficacy of K-111 in non-human primates in increasing insulin-stimulated glucose uptake and improving metabolic syndrome, assessing the general health-related effects. Six adult male obese normoglycemic prediabetic and insulin-resistant rhesus monkeys were studied on vehicle and following K-111 treatment (four-week chronic dosing each of 3 doses: 1, 3, and 10 mg/kg/d) with assessment of changes in substrate, hormone, and blood pressure measurements and alterations in insulin sensitivity using the euglycemic, hyperinsulinemic clamp technique. K-111 led to significantly decreased body weight and improved hyperinsulinemia, insulin sensitivity, hypertriglyceridemia, and HDL-cholesterol levels without adipogenesis or significant effects on fasting glucose, 24-hour urine glucose excretion, systolic or diastolic blood pressure, plasma fibrinogen, total cholesterol, or chemistry and hematology profile. These benefits are similar to the health-improving effects of calorie restriction, providing preliminary evidence that K-111 has excellent potential as a calorie-restriction mimetic agent. These results indicate the necessity of future study of K-111 for metabolic syndrome in humans, and suggest potential in reducing the risks of diabetes and cardiovascular disease.

Keywords: K-111, BM 17.0744, Hyperinsulinemia, Insulin resistance syndrome, Metabolic syndrome X, Dyslipidemia, Type 2 diabetes mellitus, Peroxisome proliferator, activated receptor α, Thiazolidinedione, Calorie restriction mimetic

\


Fig. 1. Fasting plasma insulin concentration (mean±SE) during vehicle administration, and administration of K-111 at 1, 3, or 10 mg/kg/day dose levels (F=4.6, p=0.02; significant liner trend, p=0.005). By paired t-test, both the 3 mg and the 10 mg doses were decreased compared to vehicle (p>0.05) and did not differ significantly from each other.

Link to this article

<Return

Email : bd@scprimed.com

bdprimed@gmail.com

Tel : 028-8592-1823 (in China) 

Tel:+1-517-388-6508 (in US)
Tel : +86 (28) 8592-1823 (outside of China) 

Fax : +86-28-62491302

Zip code : 610041

Address: No.88, Keyuan South Road, Hi-tech Zone, Chengdu, Sichuan Province, China

蜀ICP备2022021670号

Connect